Search

Your search keyword '"Gog, C."' showing total 119 results
Start Over Author "Gog, C."
119 results on '"Gog, C."'

9. Zusatzverfahren bei chirurgischer Therapie von Metastasen-Abhängigkeit von Primärtumor und Metastasenort

Author

Schmoll, H.-J., Wenisch, H. J. C., Encke, A., Bamberg, M., Kortmann, R. D., Görich, J., Rieber, A., Sokiranski, R., Rilinger, N., Brambs, H.-J., Wannenmacher, M., Grabbe, F., Waldenhoff, M., Fröschle, G., Jungbluth, K. H., Langendorff, H. U., Richter, H., Müller, F., Altendorf-Hofmann, A., Link, W., Hennig, F. F., Rödig, J., Meißner, A., Fell, M., Rahmanzadeh, R., Friedl, W., Göhring, U., Riedl, S., Sturm, J., Lorenz, D., Trede, M., Raab, H.-R., Nussbaum, K.-T., Werner, U., Pichlmayr, R., Lorenz, M., Staib-Sebler, E., Koch, B., Gog, C., Keck, H., Kling, N., Blumhardt, G., Bechstein, W. O., Neuhaus, P., Friedrich, J., Krause, U., Jakob, M., Eigler, F. W., Hartel, M., Winter, J., Fernandez, F., Müller, G., Markert, U., Steffen, D., Bruch, H.-P., Cohnert, T. U., Rau, H. G., Jauch, K. W., Sauter, G., Schildberg, F. W., Hartel, W., editor, and Hierholzer, G.

Published
1995
Full Text
View/download PDF

19. State of integration of palliative care at Comprehensive Cancer Centers funded by German Cancer Aid

Author

U S Schuler, S. Stiel, Jörg Hense, Michael Thomas, Lukas Radbruch, Mayer-Steinacker R, Gog C, Steffen T. Simon, P Stachura, Karin Oechsle, Viehrig M, Christoph Ostgathe, Schmitz A, Julia Berendt, Jan Gärtner, van Oorschot B, and Thuß-Patience P

Subjects
medicine.medical_specialty, Palliative care, business.industry, Medizin, Staffing, Qualitative property, General Medicine, University hospital, language.human_language, German, 03 medical and health sciences, 0302 clinical medicine, Content analysis, 030220 oncology & carcinogenesis, Family medicine, Structured interview, language, Medicine, 030212 general & internal medicine, Integrative medicine, business
Abstract

BACKGROUND Similarities and differences of integration of palliative care in clinical care, research and education structures at German Comprehensive Cancer Centers (CCC) are not known in detail. OBJECTIVE Provide an overview of availability and the way of integration of specialized palliative care at CCCs funded by the German Cancer Aid (Deutsche Krebshilfe, DKH). METHOD We conducted structured interviews from May to August 2014 with heads of palliative care departments (personally or by telephone). The interviews included a quantitative and a qualitative part. Other stakeholders of CCCs were asked the questions of the qualitative part. We evaluated the qualitative data using the content analysis by Mayring and MAXQDA 11.0. SPSS 21.0 was used for quantitative analysis. RESULTS 26 interviews were realized in 13 CCCs with 14 sites, which received funding, by DKH till August 2014 (one CCC had two university hospitals). Of these, 12 sites had a palliative care unit (86%), 11 sites had palliative care consulting services available (79%). Participation of palliative care specialists in tumor boards is not provided in 3 institutions (21%) and is often not feasible on regular basis in the other institutions, due to staffing shortage. In 7 sites (50%) defined criteria to integrate palliative care into CCCs were available. In the last 5 years specialized palliative care of 4 sites received an invitation for a research project by another department within the CCC (29%). 10 sites (71%) had started own palliative care research projects. Chairs in palliative care were available in 4 CCCs (29%). CONCLUSION The extent and depth of palliative care integration in the 14 CCC sites is heterogeneous.

Published
2016

23. Behandlung einer terminalen Dehydratation.

Author

Suchner, U., Reudelsterz, C., and Gog, C.

Subjects
DEHYDRATION prevention, PALLIATIVE treatment, DEHYDRATION, FLUID therapy, TERMINAL care, WATER intoxication
Abstract

Although dehydration is a serious condition associated with significant morbidity and mortality in palliative care patients, as in any other patient group, treatment remains controversial. A narrative review of the causes of dehydration during end of life was conducted paying special attention to the nature of terminal dehydration. A comprehensive search of the literature was performed to identify relevant articles published in English and German languages between 1960 and 2018. Currently available options for bed-side evaluation and therapeutic approaches were critically appraised and areas of future research are emphasized. The following inferences can be derived: 1) the available evidence does not support a clear decision in favor or against fluid therapy during the dying phase. 2) There is inadequate precision of the term end of life care (ELC) and insufficient differentiation between modes of dehydration of palliative care patients. 3) Evaluation of dehydration based on its clinical appearance is considered the method of choice compared to invasive procedures. 4) Detailed clinical assessment of symptom reversibility in terminal dehydration by an appropriate fluid challenge is mandatory in the decision-making process. 5) If despite adequate rehydration measures, complete reversibility of the clinical picture of dehydration can no longer be achieved since organ systems are gradually deteriorating, the cessation of clinically assisted hydration (CAH) can be considered. 6) If symptoms of dehydration are reversible after fluid challenge and no other patient wishes to the contrary are known, fluid management should be continued in the context of symptom control. 7) Hyperhydration represents a considerable threat during fluid management that needs to be prevented by noninvasive monitoring procedures. In conclusion, if CAH is applied as a part of ELC the hydration status needs to be individually appraised and all therapeutic measures constantly need to be adapted to the findings of diligent monitoring procedures. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

24. Integration der Palliativmedizin in die von der Deutschen Krebshilfe e. V. geförderten onkologischen Spitzenzentren

Author

Berendt, J., additional, Oechsle, K., additional, Thomas, M., additional, van Oorschot, B., additional, Schmitz, A., additional, Radbruch, L., additional, Simon, S., additional, Gärtner, J., additional, Thuß-Patience, P., additional, Schuler, U., additional, Hense, J., additional, Gog, C., additional, Viehrig, M., additional, Mayer-Steinacker, R., additional, Stachura, P., additional, Stiel, S., additional, and Ostgathe, C., additional

Published
2016
Full Text
View/download PDF

30. Intraperitoneal Bevacizumab (Bev) for Control of Malignant Ascites Due to Advanced-Stage Gastrointestinal Cancers (Gi): a Multicenter Double-Blind, Placebo (Pl)-Controlled, Randomized Phase Ii Study. Aio Sup-0108

Author

Jordan, K., primary, Atanackovic, D., additional, Gog, C., additional, Killing, B., additional, Stahl, M., additional, Freier, W., additional, Arnold, D., additional, Rüssel, J., additional, Hinke, A., additional, Luetkens, T., additional, Wagner, S., additional, Späth-Schwalbe, E., additional, Pelzer, U., additional, Medgenberg, D., additional, and Hegewisch-Becker, S., additional

Published
2014
Full Text
View/download PDF

36. Präferenzen und Erfahrungen in der Kommunikation mit Ärzten – Eine Befragung deutscher Patienten mit lebenslimitierenden Erkrankungen

Author

Gog, C, primary, Annweiler, B, additional, Braun, H, additional, Dathe, A, additional, Heringer, O, additional, Hübner, J, additional, Koch, S, additional, Kummer, K, additional, Müller, A, additional, Scharnagel, R, additional, Schürmann, RP, additional, Sörgel, H, additional, Sprenger, K, additional, Suchner, U, additional, Winkelmann, P, additional, Schubert, B, additional, and Schuler, U, additional

Published
2008
Full Text
View/download PDF

44. Prospective Pilot Study of Neoadjuvant Chemotherapy with 5-Fluorouracil, Folinic Acid and Oxaliplatin in Resectable Liver Metastases of Colorectal Cancer. Analysis of 42 Neoadjuvant Chemotherapies*

Author

Lorenz, M., primary, Staib-Sebler, E., additional, Gog, C., additional, Proschek, D., additional, Jauch, K.-W., additional, Ridwelski, K., additional, Hohenberger, W., additional, Gassel, H.-J., additional, Lehmann, U., additional, Vestweber, K.-H., additional, Padberg, W., additional, Zamzow, K., additional, and Müller, H.-H., additional

Published
2003
Full Text
View/download PDF

49. A Pilot Study on Intensive Weekly 24-Hour Intra-Arterial Infusion with 5-Fluorouracil and Folinic Acid for Colorectal Liver Metastases.

Author

Lorenz, Matthias, Staib-Sebler, E., Gog, C., Petrowsky, H., Köhne, C. H., and Encke, A.

Subjects
COLON cancer, CANCER research, THERAPEUTICS, METASTASIS, FOLINIC acid
Abstract

Purpose: A pilot study was performed to evaluate the tolerance and efficacy of a hepatic arterial infusion (HAI) of 5-fluorouracil (5-FU) and folinic acid (FA) in patients with unresectable liver metastases from colorectal carcinoma. Patients and Methods: In 11 patients, 135 applications of high-dose HAI of 5-FU/FA were administered. All patients had been intra-arterially pretreated, and 2 of them had received an additional intravenous therapy. The chemotherapy regimen consisted of a weekly HAI of FA 500 mg/m[sup 2] over 1 h, immediately followed by HAI of 5-FU over 24 h. Four patients received a 5-FU starting dose of 2,000 mg/m[sup 2] and 7 patients of 2,400 mg/m[sup 2] . One course consisted of 12 weekly applications interrupted by 1 week after 6 applications and 4 weeks after 12 applications. Results: The applied regimen caused only mild side effects. Nausea and vomiting were the most frequently side effects with 36 episodes out of 135 applications (WHO grade ≥3: 2 episodes). Diarrhea was a minor problem occurring with 8 episodes (WHO grade ≥3: 1 episode). There was no evidence of myelosuppression, hand-foot syndrome, neurotoxicity, and biliary sclerosis. A partial remission was observed in 3 patients, and a disease stabilization in 2 patients while the disease progressed in 6 patients under high-dose HAI of 5-FU/FA. Conclusion: The present pilot study demonstrates that the weekly high-dose HAI of 5-FU/FA is well tolerated and associated with very mild toxicity. Because of the encouraging response rate in patients, whose disease progressed under the conventional intra-arterial therapy either with 5-FU/FA or 5-fluorodeoxyuridine, this regimen seems to be an effective second-line treatment and should be evaluated in nonpretreated patients in a phase II study. [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results